Jones Charles H, Jenkins Matthew P, Adam Williams B, Welch Verna L, True Jane M
Pfizer Inc, 66 Hudson Boulevard, New York, NY, 10001, USA.
NPJ Vaccines. 2024 Feb 9;9(1):27. doi: 10.1038/s41541-024-00809-z.
Amidst the backdrop of the COVID-19 pandemic, vaccine innovation has garnered significant attention, but this field was already on the cusp of a groundbreaking renaissance. Propelling these advancements are scientific and technological breakthroughs, alongside a growing understanding of the societal and economic boons vaccines offer, particularly for non-pediatric populations like adults and the immunocompromised. In a departure from previous decades where vaccine launches could be seamlessly integrated into existing processes, we anticipate potentially than 100 novel, risk-adjusted product launches over the next 10 years in the adult vaccine market, primarily addressing new indications. However, this segment is infamous for its challenges: low uptake, funding shortfalls, and operational hurdles linked to delivery and administration. To unlock the societal benefits of this burgeoning expansion, we need to adopt a fresh perspective to steer through the dynamics sparked by the rapid growth of the global adult vaccine market. This article aims to provide that fresh perspective, offering a detailed analysis of the anticipated number of adult vaccine approvals by category and exploring how our understanding of barriers to adult vaccine uptake might evolve. We incorporated pertinent insights from external stakeholder interviews, spotlighting shifting preferences, perceptions, priorities, and decision-making criteria. Consequently, this article aspires to serve as a pivotal starting point for industry participants, equipping them with the knowledge to skillfully navigate the anticipated surge in both volume and complexity.
在新冠疫情的背景下，疫苗创新备受关注，但该领域其实已然处于一场突破性复兴的边缘。推动这些进展的是科技突破，以及人们对疫苗所带来的社会和经济效益的认识不断加深，尤其是对成年人和免疫功能低下等非儿童人群而言。与过去几十年疫苗推出能够无缝融入现有流程不同，我们预计在未来10年成人疫苗市场可能会有超过100种经过风险调整的新型产品推出，主要针对新的适应症。然而，这一领域因诸多挑战而声名狼藉：接种率低、资金短缺以及与配送和接种相关的操作障碍。为了释放这一蓬勃发展所带来的社会效益，我们需要采用全新视角来应对全球成人疫苗市场快速增长引发的动态变化。本文旨在提供这一全新视角，详细分析各类成人疫苗预计获批数量，并探讨我们对成人疫苗接种障碍的理解可能会如何演变。我们纳入了来自外部利益相关者访谈的相关见解，突出了不断变化的偏好、认知、优先事项和决策标准。因此，本文旨在成为行业参与者的关键起点，为他们提供知识，使其能够巧妙应对预计出现的数量和复杂性激增情况。
